Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received April 24, 2007
- Revision received June 14, 2007
- Accepted July 25, 2007
- Published online September 1, 2007.
Copyright & Usage
Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
Author Information
- DIPA PATEL1,
- ARMIN LAHIJI1,
- SHEETAL PATEL2,
- MATTHEW FRANKLIN2,
- XENIA JIMENEZ3,
- DANIEL J. HICKLIN1 and
- XIAOQIANG KANG1
- 1Department of Experimental Therapeutics, ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014, U.S.A.
- 2Department of Protein Science, ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014, U.S.A.
- 3Department of Antibody Technology, ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014, U.S.A.
- Correspondence to: Dr. Xiaoqiang Kang, Department of Experimental Therapeutics, ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014, U.S.A. Tel: +1 646 638 5009, e-mail: xkang{at}imclone.com
Statistics from Altmetric.com
Cited By...
Jump to section
Related Articles
Cited By...
- New therapeutic combination to enhance endocytosis of antibodies and nucleic-acid aptamers targeting EGFR in glioblastoma cells
- Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
- Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in model systems of cancer
- Modeling the dynamics of antibody-target binding in living tumors
- A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
- Immunotherapeutic approaches to ovarian cancer treatment
- Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma
- Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
- Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance
- EGFRvIII Antibody-Conjugated Iron Oxide Nanoparticles for Magnetic Resonance Imaging-Guided Convection-Enhanced Delivery and Targeted Therapy of Glioblastoma
- Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis
- Inhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2